[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:t-lymphoblastic-lymphoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":74,"states":75},"T Lymphoblastic Lymphoma",10,8,[8,16,23,30,36,42,48,54,60,67],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06561074","A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed\u002FRefractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)",[12],"Phase 2","RECRUITING","2026-08-26T02:19:24.527214Z","2026-05-05T02:43:29.027374Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06934382","Anti-CD7 CAR-T Cells in Relapsed\u002FRefractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma",[20],"Phase 1","2026-08-26T02:16:04.914942Z","2026-05-05T02:43:28.192739Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT06207123","A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed\u002FRefractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)",[27],"Phase 1\u002FPhase 2","2026-08-26T02:16:31.714843Z","2026-05-05T02:43:27.636845Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT00501826","Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",[12],"2026-08-26T02:19:14.560989Z","2026-05-05T02:43:27.590403Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT07070219","A Study of CTD402 in T-ALL\u002FLBL Patients",[27],"2026-08-26T02:17:33.002248Z","2026-05-05T02:43:27.056234Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT04972942","Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma",[20],"2026-08-26T02:17:51.502023Z","2026-05-05T02:43:26.740242Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT04315324","Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)",[27],"2026-08-26T02:16:07.529922Z","2026-05-05T02:35:31.752200Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT06446661","Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia",[],"2026-08-26T02:15:31.806698Z","2026-07-19T19:36:05.128290Z",{"nct_id":61,"title":62,"phases":63,"status":64,"updated_at":65,"content_modified":66},"NCT07137481","Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies",[12],"NOT_YET_RECRUITING","2026-08-26T02:19:17.380174Z","2026-05-05T02:43:28.805067Z",{"nct_id":68,"title":69,"phases":70,"status":71,"updated_at":72,"content_modified":73},"NCT05509855","A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007",[],"ENROLLING_BY_INVITATION","2026-08-26T02:16:09.452956Z","2026-06-16T05:54:08.033796Z",[],[76,80,84,87,90,93],{"state":77,"count":78,"slug":79},"Texas",6,"texas",{"state":81,"count":82,"slug":83},"California",4,"california",{"state":85,"count":82,"slug":86},"Illinois","illinois",{"state":88,"count":82,"slug":89},"New York","new-york",{"state":91,"count":82,"slug":92},"Pennsylvania","pennsylvania",{"state":94,"count":95,"slug":96},"Colorado",3,"colorado"]